scholarly journals Reversion of Hormone Treatment Resistance with the Addition of an mTOR Inhibitor in Endometrial Stromal Sarcoma

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
J. Martin-Liberal ◽  
C. Benson ◽  
C. Messiou ◽  
C. Fisher ◽  
I. Judson
Keyword(s):  
Hormone Receptors ◽  
Mtor Inhibitor ◽  
Acquired Resistance ◽  
Mammalian Target Of Rapamycin ◽  
Treatment Resistance ◽  
Endometrial Stromal Sarcoma ◽  
Hormone Treatment ◽  
Mtor Pathway ◽  
Low Grade ◽  
Stromal Sarcoma

Background. Endometrial stromal sarcomas (ESS) are a subtype of gynaecological sarcomas characterized by the overexpression of hormone receptors. Hormone treatment is widely used in ESS but primary or acquired resistance is common. The mammalian target of rapamycin (mTOR) pathway has been suggested to play a key role in the mechanisms of hormone resistance. Recent studies in breast and prostate cancer demonstrate that this resistance can be reversed with the addition of an mTOR inhibitor. This phenomenon has never been reported in ESS.Methods. We report the outcome of one patient with pretreated, progressing low grade metastatic ESS treated with medroxyprogesterone acetate in combination with the mTOR inhibitor sirolimus.Results. Partial response was achieved following the addition of sirolimus to the hormone treatment. Response has been maintained for more than 2 years with minimal toxicity and treatment is ongoing.Conclusion. This case suggests that the resistance to the hormone manipulation in ESS can be reversed by the addition of an mTOR pathway inhibitor. This observation is highly encouraging and deserves further investigation.

scholarly journals The prognosis of recurrent low-grade endometrial stromal sarcoma: a retrospective cohort study

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Qianwen Dai ◽  
Baolin Xu ◽  
Huanwen Wu ◽  
Yan You ◽  
Ming Wu ◽  
...  
Keyword(s):  
Surgical Treatment ◽  
Univariate Analysis ◽  
Endometrial Stromal Sarcoma ◽  
Hormone Treatment ◽  
Low Grade ◽  
Ovarian Preservation ◽  
Stromal Sarcoma ◽  
Fertility Sparing ◽  
First Recurrence

Abstract Background The prognosis of recurrent low-grade endometrial stromal sarcoma (LGESS) is little known. This study was to investigate the survival outcomes of a cohort of patients with recurrent LGESS. Methods Patients with primary LGESS diagnosed and treated for first recurrence confirmed by histology in the study center from February 2012 to June 2019 were retrospectively included. The progression-free interval (PFI) after the last treatment for first recurrence and overall survival (OS) since the diagnosis of first recurrence, which were followed up to June 1, 2020, were compared between groups of various therapy modalities. Results Fifty-six patients were included, and 43 patients (76.8%) had definite follow-up outcomes. The 5-year PFI and OS rates were 30.0% (95% confidence interval [95% CI] 29.2–30.8) and 75.0% (68.0–82.0), respectively. In univariate analysis, only fertility-sparing treatment, ovarian preservation and surgical treatment had a significant impact on the PFI (hazard ratio [HR] 4.5, 3.1, and 0.2; 95% CI 1.5–13.1, 1.3–7.3, and 0.1–0.7; and p = 0.006, 0.009 and 0.006, respectively), but no factor was found to be associated with increased mortality risk. After adjusted with hormone treatment or chemotherapy, surgical treatment had significant effectiveness on OS (HR 0.3 and 0.3, 95% CI 0.1–1.0 and 0.1–1.0, p = 0.045 and 0.049, respectively). None of the patients with fertility-sparing treatment had successful conception, and all experienced repeated relapse. Conclusion For patients with recurrent LGESS, fertility-sparing treatment or ovarian preservation should not be provided. Surgery is the treatment of choice, and hormone treatment and/or chemotherapy was effective for the survival benefits of surgical treatment.

scholarly journals CT, MRI, and FDG-PET imaging findings of low-grade extrauterine endometrial stromal sarcoma arising from the mesentery: A case report

2021 ◽  
Vol 16 (9) ◽  
pp. 2774-2779
Author(s):  
Satoshi Suzuki ◽  
Ryo Kurokawa ◽  
Tetsushi Tsuruga ◽  
Mayuyo Mori‑Uchino ◽  
Haruka Nishida ◽  
...  
Keyword(s):  
Case Report ◽  
Pet Imaging ◽  
Fdg Pet ◽  
Endometrial Stromal Sarcoma ◽  
Low Grade ◽  
Imaging Findings ◽  
Stromal Sarcoma

Low-grade endometrial stromal sarcoma developing in a postmenopausal woman under toremifene treatment for breast cancer

2012 ◽  
Vol 39 (1) ◽  
pp. 424-429 ◽  
Author(s):  
Tomoko Kashiyama ◽  
Katsutoshi Oda ◽  
Kei Kawana ◽  
Takahide Arimoto ◽  
Yukiko Kanetaka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Postmenopausal Woman ◽  
Endometrial Stromal Sarcoma ◽  
Low Grade ◽  
Stromal Sarcoma

Low-Grade Endometrial Stromal Sarcoma with Florid Intravenous Component

2008 ◽  
Vol 66 (1) ◽  
pp. 8-11 ◽  
Author(s):  
Keith Wing-Kit Lo ◽  
Mei-Yung Yu ◽  
Tak-Hong Cheung
Keyword(s):  
Endometrial Stromal Sarcoma ◽  
Low Grade ◽  
Stromal Sarcoma

scholarly journals 82 Unusual extrauterine localisation of low grade endometrial stromal sarcoma : report of two cases

2020 ◽  
Author(s):  
M Slimene ◽  
I Bouraoui ◽  
M Bouhani ◽  
S Sakhri ◽  
N Boujelbene ◽  
...  
Keyword(s):  
Endometrial Stromal Sarcoma ◽  
Low Grade ◽  
Stromal Sarcoma

scholarly journals Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung

2010 ◽  
Vol 17 (4) ◽  
pp. 977-987 ◽  
Author(s):  
Luisella Righi ◽  
Marco Volante ◽  
Ida Rapa ◽  
Veronica Tavaglione ◽  
Frediano Inzani ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Mammalian Target Of Rapamycin ◽  
Mtor Pathway ◽  
Differential Sensitivity ◽  
Initiation Factor ◽  
Target Of Rapamycin ◽  
Low Grade ◽  
Mtor Inhibition ◽  
Signaling Activation ◽  
Activation Status

Among alternative therapeutic strategies in clinically aggressive neuroendocrine tumors (NETs) of the lung, promising results have been obtained in experimental clinical trials with mammalian target of rapamycin (mTOR) inhibitors, though in the absence of a proven mTOR signaling activation status. This study analyzed the expression of phosphorylated mTOR (p-mTOR) and its major targets, the ribosomal p70S6-kinase (S6K) and the eukaryotic initiation factor 4E-binding protein 1 (4EBP1) in a large series of 218 surgically resected, malignant lung NETs, including 24 metastasizing typical carcinoids, 73 atypical carcinoids, 60 large cell neuroendocrine carcinomas (LCNECs), and 61 small cell carcinomas (SCLCs). By immunohistochemistry, low-to-intermediate-grade tumors as compared with high-grade tumors showed higher levels of p-mTOR and phosphorylated S6K (p-S6K) (P<0.001), at variance with phosphorylated 4EBP1 (p-4EBP1), which was mainly expressed in LCNECs and SCLCs (P<0.001). The activated status of mTOR pathway was proved by the strong correlation of p-mTOR with p-S6K and somatostatin receptor(s). Western blot analysis of NET tumor samples confirmed such findings, and differential sensitivity to mTOR inhibition according to mTOR pathway activation characteristics was determined in two lung carcinoid cell lines in vitro. None of the investigated molecules had an impact on survival. However, in low-grade tumors, low p-mTOR expression correlated with lymph node metastases (P=0.016), recurrent disease, and survival (P=0.005). In conclusion, these data demonstrate a differential mTOR activation status in the spectrum of pulmonary NETs, possibly suggesting that mTOR pathway profiling might play a predictive role in candidate patients for mTOR-targeted therapies.

Severe Abdominal Recurrence of Low-grade Endometrial Stromal Sarcoma After Hysteroscopic Surgery

2021 ◽  
Vol 41 (8) ◽  
pp. 4013-4016
Author(s):  
DAISUKE TAMURA ◽  
DAICHI MAEDA ◽  
KATSUHIKO ENOMOTO ◽  
HIROKAZU SATO
Keyword(s):  
Endometrial Stromal Sarcoma ◽  
Low Grade ◽  
Hysteroscopic Surgery ◽  
Stromal Sarcoma

scholarly journals Primary low-grade endometrial stromal sarcoma of the omentum

2017 ◽  
Vol 21 ◽  
pp. 119-121 ◽  
Author(s):  
Kiran Clair ◽  
Juliet Wolford ◽  
Sonia Veran-Taguibao ◽  
Grace Kim ◽  
Ramez N. Eskander
Keyword(s):  
Endometrial Stromal Sarcoma ◽  
Low Grade ◽  
Stromal Sarcoma
Sign in / Sign up

Export Citation Format

Share Document